{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:49:11Z","timestamp":1773208151344,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/s1470-2045(09)70259-1","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T07:36:37Z","timestamp":1255073797000},"page":"1063-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":490,"title":["Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study"],"prefix":"10.1016","volume":"10","author":[{"given":"Narikazu","family":"Boku","sequence":"first","affiliation":[]},{"given":"Seiichiro","family":"Yamamoto","sequence":"additional","affiliation":[]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[]},{"given":"Kuniaki","family":"Shirao","sequence":"additional","affiliation":[]},{"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[]},{"given":"Akira","family":"Sawaki","sequence":"additional","affiliation":[]},{"given":"Wasaburo","family":"Koizumi","sequence":"additional","affiliation":[]},{"given":"Hiroshi","family":"Saito","sequence":"additional","affiliation":[]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[]},{"given":"Hiroya","family":"Takiuchi","sequence":"additional","affiliation":[]},{"given":"Junichiro","family":"Nasu","sequence":"additional","affiliation":[]},{"given":"Atsushi","family":"Ohtsu","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(09)70259-1_bib1","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/S1470-2045(09)70259-1_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","article-title":"Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer","volume":"72","author":"Murad","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(09)70259-1_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a058778","article-title":"Initial or delayed chemotherapy with best supportive care in advanced gastric cancer","volume":"5","author":"Glimelius","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","article-title":"Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer","volume":"71","author":"Pyrh\u00f6nen","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(09)70259-1_bib5","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.1985.03350380077025","article-title":"A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin","volume":"253","author":"Cullinan","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/S1470-2045(09)70259-1_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1991.9.5.827","article-title":"Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer\u2014a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group","volume":"9","author":"Wils","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.1992.10.4.541","article-title":"FAMTX versus etoposide, doxorubicin and cisplatin: a randomized trial in gastric cancer","volume":"10","author":"Kelsen","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib8","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1200\/JCO.1994.12.12.2687","article-title":"Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research","volume":"12","author":"Cocconi","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","article-title":"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib10","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","volume":"18","author":"Vanhoefer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib11","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5","article-title":"A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer","volume":"71","author":"Kim","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(09)70259-1_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.1994.12.2.412","article-title":"Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer","volume":"12","author":"Cullinan","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2003.04.130","article-title":"Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205)","volume":"21","author":"Ohtsu","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.1999.17.1.319","article-title":"A phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer","volume":"17","author":"Boku","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib15","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","article-title":"Late phase II study of novel oral fluoropyrimidine aniticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients","volume":"34","author":"Sakata","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(09)70259-1_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000012099","article-title":"Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer","volume":"58","author":"Koizumi","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/S1470-2045(09)70259-1_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1016\/S1470-2045(09)70259-1_bib18","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"key":"10.1016\/S1470-2045(09)70259-1_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib20","doi-asserted-by":"crossref","unstructured":"Imamura H, IIishi H, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301\/TOP-002). 2008 Gastrointestinal Cancers Symposium; Orlando, FL, USA; Jan 25\u201327, 2008. Abstract 5.","DOI":"10.1200\/jco.2009.27.15_suppl.4544"},{"key":"10.1016\/S1470-2045(09)70259-1_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(09)70259-1_bib23","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib24","first-page":"134","article-title":"Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors","volume":"9","author":"Hoff","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S1470-2045(09)70259-1_bib25","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1200\/JCO.2005.01.917","article-title":"Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma","volume":"23","author":"Ajani","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib26","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2004.05.017","article-title":"Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil\/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT\/LV","volume":"22","author":"Shirao","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib27","doi-asserted-by":"crossref","unstructured":"Jin M, Lu H, Li J, et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1\/CDDP (SP) versus 5-FU\/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. 2008 ASCO annual meeting; Chicago, IL, USA; May 30\u2013June 3, 2008. Abstract 4533.","DOI":"10.1200\/jco.2008.26.15_suppl.4533"},{"key":"10.1016\/S1470-2045(09)70259-1_bib28","doi-asserted-by":"crossref","unstructured":"Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin\/S-1 (CS) with cisplatin\/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. 2009 ASCO annual meeting; Orlando, FL, USA; May 29\u2013June 2, 2009. Abstract 4511.","DOI":"10.1200\/jco.2009.27.15_suppl.4511"},{"key":"10.1016\/S1470-2045(09)70259-1_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/cncr.10279","article-title":"CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study","volume":"94","author":"Ajani","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(09)70259-1_bib30","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/jjco\/hyi194","article-title":"Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin","volume":"35","author":"Nagashima","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib31","doi-asserted-by":"crossref","unstructured":"Yamada Y, Yamamoto S, Ohtsu A, et al. Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. 2009 ASCO annual meeting; Orlando, FL, USA; May 29\u2013June 2, 2009. Abstract 4535.","DOI":"10.1200\/jco.2009.27.15_suppl.4535"},{"key":"10.1016\/S1470-2045(09)70259-1_bib32","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction","volume":"19","author":"Dank","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib33","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(09)70259-1_bib34","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204509702591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204509702591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:00:26Z","timestamp":1761458426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204509702591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1470204509702591"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(09)70259-1","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(09)70259-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(09)70322-5","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}